Regenxbio (RGNX) Receivables (2014 - 2025)

Regenxbio's Receivables history runs 12 years deep, the most recent figure standing at $30.7 million for Q4 2025.

• On a quarterly basis, Receivables fell 4.85% year-over-year to $30.7 million in Q4 2025; TTM through Dec 2025 was $30.7 million, a 4.85% decrease from a year earlier, with the FY2025 full-year figure at $39.6 million, down 3.56% from the prior year.
• Receivables retreated to $30.7 million in Q4 2025 per RGNX's latest filing, from $50.9 million in the prior quarter.
• Across five years, Receivables topped out at $77.7 million in Q3 2021 and bottomed at $19.4 million in Q1 2025.
• The 5-year median for Receivables is $31.4 million (2023), against an average of $39.7 million.
• Across the five-year window, Receivables tumbled 66.41% in 2023 and jumped 109.64% in 2025, its largest moves.
• Year by year, Receivables stood at $35.8 million in 2021, then increased by 0.29% to $35.9 million in 2022, then dropped by 15.02% to $30.5 million in 2023, then rose by 5.77% to $32.3 million in 2024, then declined by 4.85% to $30.7 million in 2025.
• Per Business Quant, the three latest RGNX Receivables figures stand at $30.7 million (Q4 2025), $50.9 million (Q3 2025), and $21.8 million (Q2 2025).